Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials.

@article{Pincus2006WhyAO,
  title={Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials.},
  author={Theodore Pincus and Yusuf Yazici and Ronald van Vollenhoven},
  journal={The Journal of rheumatology},
  year={2006},
  volume={33 12},
  pages={2372-5}
}
Volume 33, no. 12 care to complement clinical trials. standard for only 2 years in some settings? Need for longterm observations in Why are only 50% of courses of anti-tumor necrosis factor agents continued Theodore Pincus, Yusuf Yazici and Ronald van Vollenhoven http://www.jrheum.org/content/33/12/2372.citation J Rheumatol 2006;33;2372-2375 http://www.jrheum.org/alerts 1. Sign up for TOCs and other alerts http://jrheum.com/faq 2. Information on Subscriptions http://jrheum.com… CONTINUE READING

From This Paper

Topics from this paper.
7 Citations
55 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 55 references

Clinical epidemiology: a basic science for clinical medicine

  • D Sackett, RB Haynes, G Guyatt, P. Tugwell
  • 2006

Adherence to therapy of etanercept and infliximab during first anti-TNF treatment course in rheumatoid arthritis patients [abstract

  • L Kristensen, P Geborek, T. Saxne
  • Ann Rheum Dis 2005;64
  • 2005

Similar Papers

Loading similar papers…